Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject's parent or legal guardian has provided written informed consent/Health Insurance Portability and Accountability Act (HIPAA) authorization prior to any study-related procedures;~2. Subject has a confirmed (by Central Genetic Counselor) diagnosis of DMD as defined as:~   1. Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR~  2. Identifiable mutation within the DMD gene (deletion/duplication of one or more exons) where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, OR~  3. Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, other) that is expected to preclude production of the dystrophin protein (i.e. nonsense mutation, deletion/duplication leading to a downstream stop codon), with a typical clinical picture of DMD;~3. Subject is ≥ 4 years and \< 7 years of age at time of enrollment in the study;~4. Subject is able to complete the Time to Stand Test (TTSTAND) without assistance, as assessed at the Screening and Baseline Visits;~5. Clinical laboratory test results are within the normal range at the Screening Visit, or if abnormal, are not clinically significant, in the opinion of the Investigator. (Note: Serum gamma glutamyl transferase \[GGT\], creatinine, and total bilirubin all must be ≤ upper limit of the normal range at the Screening Visit);~6. Subject has evidence of chicken pox immunity as determined by presence of IgG antibodies to varicella, as documented by a positive test result from the testing laboratory at the Screening Visit; and~7. Subject and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.~Exclusion Criteria:~1. Subject has current or history of major renal or hepatic impairment, diabetes mellitus or immunosuppression;~2. Subject has current or history of chronic systemic fungal or viral infections;~3. Subject has had an acute illness within 4 weeks prior to the first dose of study medication;~4. Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study medication;~5. Subject has evidence of symptomatic cardiomyopathy. \[Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary\];~6. Subject is currently being treated or has received previous treatment with oral glucocorticoids or other immunosuppressive agents. \[Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical corticosteroids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration\];~7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;~8. Subject has an allergy or hypersensitivity to the study medication or to any of its constituents;~9. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;~10. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;~11. Subject is taking any other investigational drug currently or has taken any other investigational drug within 3 months prior to the start of study treatment; or~12. Subject has previously been enrolled in the study.

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Dose Level Group 1 (Type: EXPERIMENTAL): Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
- Dose Level Group 2 (Type: EXPERIMENTAL): Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
- Dose Level Group 3 (Type: EXPERIMENTAL): Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
- Dose Level Group 4 (Type: EXPERIMENTAL): Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).